Ardelyx (ARDX) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year price targets for Ardelyx's shares. Their ARDX share price forecasts range from $3.00 to $8.00. On average, they anticipate the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 77.6% from the stock's current price.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts.

Ardelyx's stock was trading at $2.85 at the start of the year. Since then, ARDX shares have increased by 23.5% and is now trading at $3.52.
View the best growth stocks for 2023 here.

Ardelyx saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 16,690,000 shares, a decline of 8.5% from the April 30th total of 18,240,000 shares. Based on an average daily volume of 7,350,000 shares, the short-interest ratio is presently 2.3 days.
View Ardelyx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ARDX earnings forecast.

Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings results on Wednesday, May, 3rd. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company had revenue of $11.37 million for the quarter, compared to analysts' expectations of $10.08 million. Ardelyx had a negative net margin of 104.52% and a negative trailing twelve-month return on equity of 76.72%.

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB),

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (7.09%), BlackRock Inc. (1.73%), Renaissance Technologies LLC (1.46%), Two Sigma Investments LP (1.33%), Price T Rowe Associates Inc. MD (1.19%) and Bank of America Corp DE (0.97%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends.

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARDX stock can currently be purchased for approximately $3.52.

Ardelyx (NASDAQ:ARDX) has a market capitalization of $754.91 million and generates $63.06 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.